COVID 19 Spike S RBD Domain Coronavirus (COVID-19) Antibody – Monoclonal

Human monoclonal anti-spike RBD domain (SARS-CoV-2/COVID-19) antibody produced by in vitro HEK293 cell culture.

The novel coronavirus (SARS-CoV-2), previously called 2019-nCoV, is a newly identified coronavirus causing the ongoing outbreak of atypical pneumonia in Wuhan China from late 2019.

The genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain (RCB) of SARS-CoV-2 shares only 40% amino acid identity with other SARS-related coronaviruses.

Small volumes of anti-COVID-19 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS434259 is an antibody targeting COVID-19. Also known as Anti-Spike RBD Domain (SARS-CoV-2) Human Monoclonal Antibody.